Recent Publications

1. HASSLACHER, C;  KULOZIK, F; PLATTEN, I; KRAFT, M; SIEGEL, EG:
Serum zonulin as parameter of intestinal permeability in longstanding type 2 diabetes: correlations with metabolism parameter and renal function.
J Diabetes Metab Disord Control. 2018;5(2):58–62.

2. SIEGEL, EG; PLATTEN, I; KRAFT, M ; LORENZO BERMEJO, J; HASSLACHER C:
Composition of intestinal microbiome and barrier function in Type 2 diabetic patients
and nondiabetic controls.
Diab Obes Metab Disor 2018; 4: 10-15

3. SIEGEL, EG; LORENZO BERMEJO, J; FLADE, I; HASSLACHER, C:
Cardiovascular Complications and Composition of the Intestinal
Microbiome in Patients with Type 2 Diabetes.
Int J Diabetes Clin Res 2018, 5:086, DOI: 10.23937/2377-3634/1410086

4. HASSLACHER, C; LORENZO BERMEJO, J:
Treatment with insulin analogs and prevalence of cardiovascular complications in patients with type 1 diabetes.
Ther Adv Endocrinol Metab. 2017 Nov;8(11):149-157. doi: 10.1177/2042018817732732. Epub 2017 Oct 10

5. SCHINDLER, C; BIRKENFELD, AL; HANEFELD, M;  SCHATZ, U; KÖHLER,C;  GRÜNEBERG, M;  TSCHÖPE, D; BLÜHER, M; HASSLACHER, C; BORNSTEIN, SR:
Intravenous ferric carboxymaltose for improvement of metabolic parameters in people with Type 2 diabetes mellitus and iron deficiency – the CLEVER trial: a randomised, single blind, proof-of-concept study.
Diabetes Ther. 2017 Nov 13. doi: 10.1007/s13300-017-0330-z. [Epub ahead of print]

6. MUELLER, AJ; HASSLACHER, C;  KRIVÁNEK, R; KNUTH, M; NIKOLAUS, K; KRIVÁNEKOVÁ, L:
Clinical feasibility and home use study of a percutaneous optical fiber glucose sensor
Diabetes Technology Meeting 2017 (2 November 2017, Washington)

7. SIEGEL, E; PLATTEN, I; KRAFT, M; LORENZO-BERMEJO, J; HASSLACHER, C:
The gut microbiom and cardiovascular complications in patients with type 2 diabetes.
53 rd EASD Annual Meeting; Lisbon, Portugal, 11 - 15 September 2017.
Diabetologia. 2017 Sep;60(Suppl 1) S515; doi: 10.1007/s00125-017-4350-z.

8. HASSLACHER, C; KULOZIK, F:
Effect of renal function on serum concentration of 1,5-anhydroglucitol in type 2 diabetic patients in chronic kidney disease stages I-III: A comparative study with HbA1c and glycated albumin. (Supplementary)
http://biomedical-advances.org/diabetes-20175-4/

9. FLACKE, F; EDELMAN, S: BAIN, S;HASSLACHER, C; CHARPENTIER, G; VESPASIANI, G; GOYEAU, H; WOLOSCHAK, M; DAVIES M:
Device-supported vs routine titration of insulin glargine 300 U/ml (Gla-300) in type 2 diabetes: efficacy and safety
53 rd EASD Annual Meeting; Lisbon, Portugal, 11 - 15 September 2017.
Diabetologia. 2017 Sep;60 (Suppl 1) S307; doi: 10.1007/s00125-017-4350-z.

10. SCHLOSSER, M; HASSLACHER, C; WOLF, G:
Nephropathie bei Diabetes 1.
Diabetologie 2017; 12 (Suppl 2): 115-120

Publikationsliste

A - Original Articles

B - Oral_Poster Presentations

C - Reviews, Editorials

D - Book chapters

E - Editor Activities

F - Scientific Videos, Awards